REG - Avacta Group PLC - Issue of Equity and Total Voting Rights

AvactaAnnouncement

Wed 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260513:nRSM0544Ea&default-theme=true

RNS Number : 0544E  Avacta Group PLC  13 May 2026

Avacta Group plc

("Avacta", the "Group" or the "Company")

 

Issue of Equity and Total Voting Rights

 

 

LONDON and PHILADELPHIA - May 13, 2026 - Avacta Therapeutics (AIM: AVCT, "the
Company", "Avacta"), a clinical stage biopharmaceutical company developing
pre|CISION(®), a tumor-activated oncology delivery platform, today announces
it has issued and allotted a total 1,604,063 new ordinary shares of 10 pence
each in the Company ("New Ordinary Shares").

 

The New Ordinary Shares are being issued in settlement of a Notice of
Conversion for £1.20 million of the principal amount of the Company's
unsecured convertible bond (the "Conversion").

 

As a result of the Conversion, the principal remaining under the convertible
bond will be reduced by £1.20 million to £19.20 million.

 

Admission and Total Voting Rights

 

Application has been made to AIM for the admission to trading of the 1,604,063
New Ordinary Shares to trading on AIM ("Admission"). It is expected Admission
will become effective and dealings in such Ordinary Shares will commence at
8.00 am on or around 18 May 2026. The New Ordinary Shares will rank pari passu
in all respects with the existing Ordinary Shares of the Company.

 

Immediately following Admission, the Company's enlarged issued share capital
will be 457,892,574 Ordinary Shares. This figure may be used by shareholders
in the Company as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

-Ends-

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                   https://avacta.com/ (https://avacta.com/)

 Christina Coughlin, Chief Executive Officer        via Cohesion Bureau

 Strand Hanson Limited (Nominated Adviser)          www.strandhanson.co.uk (http://www.strandhanson.co.uk)

 James Harris / Chris Raggett / James Dance

 Zeus (Broker)                                      www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry / Dominic King

 Cohesion Bureau                                    avacta@cohesionbureau.com (mailto:avacta@cohesionbureau.com)

 Communications / Media / Investors

 Richard Jarvis

 

About Avacta - https://avacta.com/ (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies through its proprietary pre|CISION®
platform. pre|CISION® is a payload delivery system based on a tumor-specific
protease (Fibroblast Activation Protein or FAP) that is designed to
concentrate highly potent payloads in the tumor microenvironment while sparing
normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC)
are a novel entry to the XDC drug class, leveraging the success of antibody
drug conjugates with alternative methods of delivery beyond antibodies.

 

Our pre|CISION® PDCs leverage this tumor-specific release mechanism to
provide unique benefits over traditional antibody drug conjugates, releasing
active payload in the tumor and reducing systemic exposure and toxicity which
enables dosing to be optimized to deliver the best outcomes for patients. The
lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled
pre|CISION® version of doxorubicin that delivers the payload directly in the
tumor with limited peripheral blood exposure and has demonstrated preliminary
activity in tumor types sensitive to doxorubicin including salivary gland
cancer and soft tissue sarcoma.

 

About AVA6103 (FAP-Exd)

 

AVA6103 is the second clinical candidate and is based on the innovative
pre|CISION(®) sustained release mechanism that provides for prolonged release
of payload directly in the tumor, minimizing systemic exposure.  AVA6103 is
being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers
with Unmet needS). Preclinical data suggest this approach has optimized
payload delivery with a high intratumoral concentration and prolonged exposure
of released payload in the tumor, coupled with limited systemic exposure to
the released payload.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEMZGMKNZDGVZM



            Copyright 2019 Regulatory News Service, all rights reserved